Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Merck Serono
 More »

  • "A New Model in Clinical Development": Merck Serono Teams Up...
    Merck Serono, a division of Merck, and contract research company Quintiles have entered a new five-year clinical development agreement, one that the firms are describing as the ...
    5-15-2013
  • Biotechs Need to Walk the Walk on Drug Value
    In June 2012, Massachusetts joined with Abbott, Biogen Idec, EMD Serono, Janssen, Merck & Co., Pfizer, and Sunovion Pharmaceuticals to form the Massachusetts Neuroscience ...
    5-15-2013
  • Amgen Forms Joint Venture to Sell Vectibix in China
    that Vectibix was at least as effective as rival drug Erbitux (cetuximab), marketed by Eli Lilly and Merck Serono, as a single agent for mCRC patients with wild-type KRAS tumors. ...
    5-10-2013
  • GEN | Biolinks
    ... Merck KGaA Merck Millipore Merck Serono SA Merrimack Pharmaceuticals, Inc Mersana Therapeutics, Inc Metabolex, Inc Metabolic Solutions Development Co. Metabolomic Discoveries Gmbh ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    In June 2012, Massachusetts joined with Abbott, Biogen Idec, EMD Serono, Janssen, Merck & Co., Pfizer, and Sunovion Pharmaceuticals to form the Massachusetts Neuroscience ...
    4-22-2013
  • EMD Serono Expanding R&D Hub in Billerica, MA
    Merck KGaA's EMD Serono subsidiary said today it will expand its U.S. workforce about 20% by 2014 by expanding its R&D hub about 25 miles northwest of Boston, in Billerica, MA. EMD ...
    4-18-2013
  • Cetrotide Manufacturing Rights Transferred to Merck Serono
    Aeterna Zentaris' German subsidiary transferred manufacturing rights and granted a manufacturing license for Cetrotide® to Merck Serono. The deal is expected to be finalized on or ...
    4-17-2013
  • Merck Serono Creates New Research Innovation Model
    Merck Serono set up a novel research collaboration to start innovative projects under the roof of a center operated by BioMed X. The new lab will focus on established a completely ...
    4-3-2013
  • Top 10 Biopharma Layoffs of 2012
    of U.S. pharmaceuticals operations. 4. Merck KGaA Total workforce reduction: 1,600 jobs ... part of a cost-cutting consolidation following the company's 2006 acquisition of Serono. ...
    3-15-2013
  • Top 10 Biopharma Layoffs of 2012
    ... hundred" additional jobs in 2013. #4. Merck KGaA Total workforce reduction: 1,600 jobs ... part of a cost-cutting consolidation following the company's 2006 acquisition of Serono. ...
    2-15-2013
  • Progressive MS Therapy Sparks Deal Worth Up to $225M
    Opexa Therapeutics said today it granted Merck Serono an option for exclusive license to develop and commercialize Tcelna (imilecleucel-T), an investigational personalized T-cell ...
    2-5-2013
  • Prexton Licenses Domain's Parkinson's Disease Drug
    Domain Therapeutics granted Prexton Therapeutics, a spin-off company of Merck Serono, an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive ...
    1-22-2013
  • Top 10 Biggest Biopharma Marketing Fines
    ... of community service working with drug rehabilitation programs. #8. Serono (now Merck Serono) Amount of Fine: $704 million Drug(s) Involved: Serostim (recombinant DNA ...
    1-21-2013
  • Merck Serono Launches IT Services Company
    Merck Serono, a division of Merck, has formed the fourth company stemming from its Entrepreneur Partnership Program (EPP). The new company, dubbed TQM Insight, is a services ...
    1-15-2013
  • MS Research Gets $1.4M Boost
    steering committee comprised of Fast Forward staff and representatives from EMD Serono and Merck KGaA. The organizations that will receive funding under the Accelerating ...
    12-21-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll